Chronic low-dose intravenous immunoglobulins as steroid-sparing therapy in myasthenia gravis.

This retrospective study demonstrates that chronic low-dose IVIg treatment in patients with MG improves clinical outcomes and has a prolonged and significant steroid-sparing effect over a period of 3 years.